Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jul;97(3):763–768. doi: 10.1111/j.1476-5381.1989.tb12014.x

Central nervous system kinin receptors and the hypertensive response mediated by bradykinin.

C J Lindsey 1, C R Nakaie 1, D T Martins 1
PMCID: PMC1854576  PMID: 2547484

Abstract

1. Bradykinin (Bk) administered intracerebroventricularly to the rat causes an increase in arterial pressure. 2. Analogues of Bk with agonist and antagonist activity were injected, over a wide dose-range, into the posterior region of the fourth ventricle of unanaesthetized rats implanted with permanent ventricular canullae, and blood pressure was measured directly from the abdominal aorta. 3. The analogues Ile-Ser-Bk (T-kinin) and Lys-Lys-Bk, which interact with both B1 and B2 Bk receptors, produced pressor effects similar to those of Bk, although of greater duration, whereas des-Arg9-Bk, a B1-receptor agonist, had no effect. 4. The B1-antagonist des-Arg9-[Leu8]-Bk did not alter the Bk pressor response, but D-Arg-[Hyp3, Thi5,8,D-Phe7]-Bk, which interacts both with B1- and B2-receptors blocked the responses to Bk, T-kinin and Lys-Lys-Bk and caused parallel shifts to the right of the Bk dose-response curves. Neither antagonist, by itself, had any effect on blood pressure. 5. It is concluded that the central pressor response to Bk is mediated by receptors of the B2 subtype.

Full text

PDF
763

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlas A., Okamoto H., Greenbaum L. M. T-kininogen--the major plasma kininogen in rat adjuvant arthritis. Biochem Biophys Res Commun. 1985 May 31;129(1):280–286. doi: 10.1016/0006-291x(85)91434-2. [DOI] [PubMed] [Google Scholar]
  2. Braas K. M., Manning D. C., Perry D. C., Snyder S. H. Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors. Br J Pharmacol. 1988 May;94(1):3–5. doi: 10.1111/j.1476-5381.1988.tb11492.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Correa F. M., Graeff F. G. Central mechanisms of the hypertensive action of intraventricular bradykinin in the unanaesthetized rat. Neuropharmacology. 1974 Jan;13(1):65–75. doi: 10.1016/0028-3908(74)90008-2. [DOI] [PubMed] [Google Scholar]
  4. Corrêa F. M., Graeff F. G. Central site of the hypertensive action of bradykinin. J Pharmacol Exp Ther. 1975 Mar;192(3):670–676. [PubMed] [Google Scholar]
  5. Graeff F. G., Pelá I. R., Roch e Silva M. Behavioural and somatic effects of bradykinin injected into the cerebral ventricles of unanaesthetized rabbits. Br J Pharmacol. 1969 Nov;37(3):723–732. doi: 10.1111/j.1476-5381.1969.tb08511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Guimarães J. A., Vieira M. A., Camargo M. J., Maack T. Renal vasoconstrictive effect of kinins mediated by B1-kinin receptors. Eur J Pharmacol. 1986 Nov 4;130(3):177–185. doi: 10.1016/0014-2999(86)90266-9. [DOI] [PubMed] [Google Scholar]
  7. Lang W. J., Pearson L. Studies on the pressor responses produced by bradykinin and kallidin. Br J Pharmacol Chemother. 1968 Feb;32(2):330–338. doi: 10.1111/j.1476-5381.1968.tb00976.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lindsey C. J., Bendhack L. M., Paiva A. C. Effect of pH on the inhibition of angiotensin converting activity by enalaprilat in the rat perfused mesenteric vascular bed. J Pharmacol Exp Ther. 1987 Oct;243(1):292–296. [PubMed] [Google Scholar]
  9. Llona I., Vavrek R., Stewart J., Huidobro-Toro J. P. Identification of pre- and postsynaptic bradykinin receptor sites in the vas deferens: evidence for different structural prerequisites. J Pharmacol Exp Ther. 1987 May;241(2):608–614. [PubMed] [Google Scholar]
  10. Okamoto H., Greenbaum L. M. Isolation and structure of T-kinin. Biochem Biophys Res Commun. 1983 Apr 29;112(2):701–708. doi: 10.1016/0006-291x(83)91519-x. [DOI] [PubMed] [Google Scholar]
  11. Okamoto H., Greenbaum L. M. Pharmacological properties of T-kinin (isoleucyl-seryl-bradykinin) from rat plasma. Biochem Pharmacol. 1983 Sep 1;32(17):2637–2638. doi: 10.1016/0006-2952(83)90039-4. [DOI] [PubMed] [Google Scholar]
  12. Pearson L., Lambert G. A., Lang W. J. Centrally mediated cardiovascular and EEG responses to bradykinin and eledoisin. Eur J Pharmacol. 1969 Nov;8(2):153–158. doi: 10.1016/0014-2999(69)90070-3. [DOI] [PubMed] [Google Scholar]
  13. Pearson L., Lang W. J. Effect of acetylsalicylic acid and morphine on pressor responses produced by bradykinin. Eur J Pharmacol. 1969 Apr;6(1):17–23. doi: 10.1016/0014-2999(69)90059-4. [DOI] [PubMed] [Google Scholar]
  14. Regoli D., Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980 Mar;32(1):1–46. [PubMed] [Google Scholar]
  15. Regoli D., Drapeau G., Rovero P., Dion S., D'Orléans-Juste P., Barabé J. The actions of kinin antagonists on B1 and B2 receptor systems. Eur J Pharmacol. 1986 Apr 9;123(1):61–65. doi: 10.1016/0014-2999(86)90687-4. [DOI] [PubMed] [Google Scholar]
  16. Roblero J., Ryan J. W., Stewart J. M. Assay of kinins by their effects on blood pressure. Res Commun Chem Pathol Pharmacol. 1973 Jul;6(1):206–212. [PubMed] [Google Scholar]
  17. Sakamoto W., Satoh F., Gotoh K., Uehara S. Ile-Ser-bradykinin (T-kinin) and Met-Ile-Ser-bradykinin (Met-T-kinin) are released from T-kininogen by an acid proteinase of granulomatous tissues in rats. FEBS Lett. 1987 Jul 27;219(2):437–440. doi: 10.1016/0014-5793(87)80267-3. [DOI] [PubMed] [Google Scholar]
  18. Vavrek R. J., Stewart J. M. Competitive antagonists of bradykinin. Peptides. 1985 Mar-Apr;6(2):161–164. doi: 10.1016/0196-9781(85)90033-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES